MedTrace Logo

Blueberry-protein Supplementation and Exercise

NCT05596500 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2023-06-09

No results posted yet for this study

Summary

This study is the human clinical trial component of an SBIR grant with Sinnovatek (funded). Cyclists (n=20) will consume a blueberry-protein, blueberry, or placebo supplement for 2 weeks prior to cycling for 2.5 h at high intensity. Washout periods (2 weeks) will separate the 3 trials, and the cyclists will crossover (randomized) to one of the two others supplements for 2 weeks, and then engage in additional 2.5 h cycling bouts. Blood and urine samples will be collected pre- and post-supplementation for each of the 3 trials. Blood samples will also be collected immediately after and 1.5h- and 24h-post-exercise. Blood samples will be analyzed for inflammation and oxidative stress outcomes. Urine samples will be analyzed for blueberry gut-derived phenolics.

Conditions

  • Inflammatory Response

Interventions

DIETARY_SUPPLEMENT

Blueberry-protein gel

Sport gel with blueberry extract and plant protein.

DIETARY_SUPPLEMENT

Blueberry gel

Sport gel with blueberry extract only.

DIETARY_SUPPLEMENT

Placebo

Sport gel without the blueberry extract polyphenols and without protein.

Sponsors & Collaborators

  • SinnovaTek

    collaborator UNKNOWN

  • North Carolina State University

    collaborator OTHER

  • Appalachian State University

    lead OTHER

Principal Investigators

  • David C Nieman, DrPH · Appalachian State Univ

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-15
Primary Completion
2023-06-01
Completion
2023-06-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05596500 on ClinicalTrials.gov